Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 6 | 2024 | 459 | 1.130 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2021 | 22 | 0.870 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 3 | 0.760 |
Why?
|
| Cancer Survivors | 2 | 2024 | 43 | 0.360 |
Why?
|
| Lymphoma, B-Cell | 1 | 2009 | 18 | 0.320 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 12 | 0.320 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2009 | 13 | 0.320 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2009 | 3 | 0.310 |
Why?
|
| Etoposide | 1 | 2009 | 19 | 0.310 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 679 | 0.300 |
Why?
|
| Heart Diseases | 1 | 2009 | 70 | 0.300 |
Why?
|
| Piperazines | 2 | 2022 | 47 | 0.260 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2006 | 15 | 0.260 |
Why?
|
| Interferons | 1 | 2006 | 69 | 0.250 |
Why?
|
| Cardiomyopathies | 1 | 2006 | 33 | 0.250 |
Why?
|
| E-Selectin | 2 | 2016 | 27 | 0.250 |
Why?
|
| Libido | 1 | 2024 | 1 | 0.230 |
Why?
|
| Bupropion | 1 | 2024 | 2 | 0.230 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 67 | 0.220 |
Why?
|
| Female | 10 | 2024 | 15153 | 0.200 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 23 | 0.190 |
Why?
|
| Humans | 11 | 2024 | 28094 | 0.190 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 33 | 0.190 |
Why?
|
| Salivary Ducts | 1 | 2021 | 3 | 0.190 |
Why?
|
| Pyridines | 1 | 2022 | 107 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 409 | 0.150 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2017 | 9 | 0.140 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2017 | 9 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 25 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 82 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 163 | 0.120 |
Why?
|
| Aptamers, Nucleotide | 1 | 2015 | 13 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 330 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 298 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 263 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 325 | 0.100 |
Why?
|
| Aged | 4 | 2024 | 5400 | 0.100 |
Why?
|
| Middle Aged | 4 | 2024 | 7137 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 1013 | 0.090 |
Why?
|
| Aging | 1 | 2018 | 968 | 0.090 |
Why?
|
| Adult | 3 | 2024 | 7739 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Trisomy | 1 | 2009 | 19 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 42 | 0.080 |
Why?
|
| Rituximab | 1 | 2009 | 63 | 0.080 |
Why?
|
| Eosinophils | 1 | 2009 | 6 | 0.080 |
Why?
|
| Imatinib Mesylate | 1 | 2009 | 14 | 0.080 |
Why?
|
| Benzamides | 1 | 2009 | 34 | 0.080 |
Why?
|
| Survival Rate | 2 | 2022 | 430 | 0.080 |
Why?
|
| Recurrence | 1 | 2009 | 322 | 0.070 |
Why?
|
| Meningioma | 1 | 2009 | 79 | 0.070 |
Why?
|
| Male | 4 | 2017 | 13489 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 463 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2009 | 125 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 329 | 0.070 |
Why?
|
| Chest Pain | 1 | 2006 | 26 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2006 | 17 | 0.060 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2024 | 6 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2024 | 417 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 15 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 24 | 0.050 |
Why?
|
| Phthalazines | 1 | 2022 | 22 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2009 | 2377 | 0.050 |
Why?
|
| Pregnancy | 1 | 2006 | 1191 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 226 | 0.050 |
Why?
|
| Oxyhemoglobins | 1 | 2018 | 10 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 92 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 487 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 104 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 181 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 125 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 247 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2018 | 193 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 433 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 31 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 301 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 138 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 315 | 0.030 |
Why?
|
| Complement C5a | 1 | 2015 | 5 | 0.030 |
Why?
|
| Complement C3a | 1 | 2015 | 6 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 20 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 276 | 0.030 |
Why?
|
| Mice, Inbred ICR | 1 | 2015 | 26 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 27 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 65 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 269 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 25 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 85 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 802 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 224 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 373 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 473 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 607 | 0.030 |
Why?
|
| Kidney | 1 | 2015 | 286 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1591 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 848 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 2021 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 806 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2015 | 612 | 0.030 |
Why?
|
| Cytokines | 1 | 2015 | 447 | 0.030 |
Why?
|
| Apoptosis | 1 | 2016 | 775 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 440 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 765 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 10415 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 2546 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 4650 | 0.020 |
Why?
|